Skip to main content
. 2017 Jan 13;49(1):e282. doi: 10.1038/emm.2016.120

Figure 2.

Figure 2

The validation of the CCNE1 signature in an independent cohort. Progression-free survival of two patient groups classified by the CCNE1 signature (a) in the Swedish cohort (n=97) and (b) in the European cohort (n=302).